研究单位：[1]Eli Lilly and Company[2]The First People's Hospital of Yunnan Province Kunming,Yunnan,China,650034[3]First Affiliated Hosp of College of Med,Zhejiang University Hangzhou,Zhejiang,China,310003[4]The Second Affiliated Hospital of Zhejiang University School of Medicine Hangzhou,Zhejiang,China,310009[5]Sir Run Run Shaw Hospital Hangzhou,Zhejiang,China,310016[6]The Second Affiliated Hospital YuYing Childens Hospital of Wenzhou Medical university Wenzhou,Zhejiang,China,310015[7]Liaocheng People's Hospital Liaocheng,China,252000[8]Vojenská Nemocnice Brno Brno,Brno-město,Czechia,636 00
This study is designed to evaluate the long-term efficacy and safety of mirikizumab in participants with moderately to severely active ulcerative colitis (UC).
